This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ESMO, Barcelona, Spain 26-30 September 2019

Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours

Nicolas Girard, Björn Hackanson, Martin Wermke, Fabrice Barlesi, Harald Timotheus Landsteiner, Girish Jayadeva, Jürgen Alt

Girard 1336.11 Tip Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

RELATED INFORMATION

VEGF/Ang2 inhibitor

BI 836880 is a humanised bispecific nanobody® comprising blocking domains for both VEGF and Ang2

PD-1 inhibitor (BI 754091)

BI 754091 is a PD-1 inhibitor that binds to the PD-1 receptor, thereby blocking signalling downstream from PD-1 and allowing T cell-mediated tumour cell destruction

RELATED INFORMATION

VEGF/Ang2 inhibitor

BI 836880 is a humanised bispecific nanobody® comprising blocking domains for both VEGF and Ang2

PD-1 inhibitor (BI 754091)

BI 754091 is a PD-1 inhibitor that binds to the PD-1 receptor, thereby blocking signalling downstream from PD-1 and allowing T cell-mediated tumour cell destruction

ESMO 2019 Congress

Find information on Boehringer Ingelheim’s activities at ESMO 2019
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

image